AQEMIA Boosts Series A Funding to €60M to Accelerate on its Proprietary Therapeutic Pipeline
This new investment follows recent successes in drug discovery projects led by AQEMIA alongside the entire drug discovery value chain, one of the clearer illustrations being the recent
AQEMIA will leverage this new funding to accelerate the growth of its wholly-owned pipeline of drug discovery projects and assets as well as further scale its proprietary GenAI and deep physics drug discovery platform. AQEMIA’s internal pipeline is already counting several projects being tested in animals, mostly in oncology and immuno-oncology, and the next phase of projects will cover the full spectrum of therapeutic areas.
As AQEMIA moves forward with this fundraise, it is poised to intensify its mission of reshaping the drug discovery landscape. By expanding the team with top-tier talents and pushing technological boundaries, AQEMIA reaffirms its commitment to leading the change in a new era of drug discovery innovation.
“We embark on this next chapter of our history to accelerate our drug discovery programs, to build a larger proprietary pipeline beyond our projects already tested in animals, and to shape a global organization that embraces generative AI and rigorous physics as key instruments to bring excellence in small molecule drug discovery. AQEMIA's journey continues: We're advancing to clinical trials.” said
“The technology developed by AQEMIA from fundamental research and applied to medical research is unique in the world. We are delighted to be supporting this team, led by
About AQEMIA
AQEMIA is a next-gen pharmatech company generating one of the world's fastest-growing drug discovery pipeline. Our mission is to design fast innovative drug candidates for dozens of critical diseases. Our differentiation lies in our unique quantum and statistical mechanics algorithms fueling a generative artificial intelligence to design novel drug candidates, with already several drug discovery successes in internal pipeline as well as in collaboration with Pharma companies.
About Wendel Growth
Through Wendel Growth, Wendel invests via funds or directly in innovative, high-growth companies. Having already committed over €200 million in recent years, Wendel Growth is looking for direct investment and co-investment opportunities in start-ups. To make these direct investments, like the one made in 2019 in AlphaSense, Wendel is relying on a new team made up of two experienced professionals in this asset class. Wendel's ambition is to invest up to €50 million per unit in scale-ups in
About
Large Venture - the late-stage VC arm of
Visit us at bpifrance.com -
About Eurazeo
Eurazeo is a leading European investment group with €33.5 billion in diversified assets under management, including €23 billion on behalf of institutional and private clients through its private equity, private debt, real estate and infrastructure strategies. The Group supports more than 600 mid-market companies, leveraging the commitment of its 400 employees, its sector expertise, its privileged access to global markets via 12 offices in
Eurazeo has offices in
Eurazeo is listed on Euronext Paris.
ISIN : FR0-00121121 - Bloomberg- : RF FP - Reuters : EURA.PA.
About
We are proud to have been an active partner in over 100 startups including success stories such as
Learn more https://www.elaia.com • @Elaia_Partners
View source version on businesswire.com: https://www.businesswire.com/news/home/20240129209892/en/
Press
AQEMIA
E
urazeo
B
pifrance
E
laia
Source: AQEMIA
